

1 The Effects of Hyperoxia on Repeated Sprint Cycling Performance & Muscle Fatigue

2

3

4

5

6

7

8

9

10 Word count: 3174 excluding abstract /refs

11 Abstract 250

12 Tables: 1

13 Figures: 2

14

15 **Abstract**

16 **Objectives:** Hyperoxia (> 21% oxygen) can evoke performance improvements in aerobic and
17 anaerobic exercise. The aims of the current study were to determine the effects of breathing
18 hyperoxic gas (fraction of inspired oxygen [F_{iO_2}] 1.00) on repeated cycle performance, and to
19 assess the nature and extent of fatigue after intermittent sprinting.

20 **Design & Methods:** Testing (n=14 males) comprised two visits to the laboratory. Each
21 session involved 10 x 15s repeated cycle sprints breathing FiO_2 1.00 (hyperoxia) or FiO_2 0.21
22 (normoxia). Muscle fatigue was measured pre and post sprints using maximal voluntary
23 contraction (MVC), voluntary activation (VA) and potentiated doublet twitch (PTF). Blood
24 lactate (BLa) was taken between sprints.

25 Paired samples t-tests were used to examine difference between conditions in power output
26 (peak and mean Watts) and BLa. Two-way ANOVA was used to examine fatigue variables
27 pre and post sprints according to condition.

28 **Results:** Mean power output was 4% greater in hyperoxia ($p < 0.01$), with no difference in peak
29 power ($p > 0.05$). There was a significant increase in BLa in hyperoxia compared with normoxia
30 ($p < 0.01$) in sprints 4 and 8, as well as meaningful difference in sprints 4-10. There was no
31 significant difference in fatigue factors (MVC, VA and PTF) ($p > 0.05$) in response to the cycling,
32 although a large drop in PTF occurred in both conditions.

33 **Conclusion:** Hyperoxia can elicit improvements in mean cycling power, with no significant
34 change in post exercise muscle fatigue. Hyperoxia as a training aid may provide performance
35 enhancing effects during repeated sprint cycling by reducing concurrent muscle fatigue,
36 primarily via peripheral factors.

37 **Keywords:** Oxygen, Power, Lactate, Training, Sprinting.

38 Introduction

39 Hyperoxia is the inhalation of air with a fraction of inspired oxygen (FiO_2) greater than that of
40 sea level (20.9%). Supplementing high intensity exercise with $FiO_2 >0.21$ allows the
41 maintenance of performance when fatigue would usually become apparent, both during
42 aerobic and sprint exercise^{1,2}. The mechanism behind this attenuation of performance decline
43 are multifactorial and include reduced production of blood lactate (BLa)¹, enhanced clearance
44 of BLa, prevention of muscle oxygen desaturation^{3,4} the maintenance of blood pH and
45 enhanced resynthesis of creatine phosphate⁵. These factors are associated with peripheral
46 fatigue; i.e. the exercise induced decrease in muscle force production.

47 A reduction in neural drive from the motor cortex to muscle appears as a decrease in voluntary
48 muscle activation (VA) during exercise⁶. This 'central fatigue', may also be influenced by the
49 fraction of inspired air. Indeed, research has shown that a reduced cerebral O_2 delivery
50 resulting from hypoxia (FiO_2 0.18) results in curtailment of exercise performance due to
51 fatigue⁷. Thus, whether hyperoxia can alleviate central fatigue in a sport situation is unknown.

52 Performance decline is likely a combination of both central and peripheral factors and the
53 relative contribution of each depends upon the nature of the task⁸. Peripheral fatigue is likely
54 the limiting factor in short, high intensity exercise, with central fatigue playing a greater role as
55 the exercise bout continues. For example, a single 4 km time trial lasting around 5 minutes
56 was shown to be limited by peripheral fatigue, whilst a 20 km trial (lasting around 32 minutes)
57 was primarily limited by central fatigue⁸.

58 Repeated sprint efforts represent a short term high intensity exercise, which are likely to be
59 limited primarily by peripheral fatigue⁹. However, the extent to which central fatigue
60 contributes to performance decline in repeated sprint performance is equivocal. Racinais *et*
61 *al.*,¹⁰ determined that the ability to repeat short duration sprints was associated with both
62 central and peripheral factors. The twitch interpolation technique is widely used and is

63 considered a reliable method to estimate the origin of neuromuscular fatigue. Peripheral
64 fatigue is measured by comparing the force responses to electrical stimulation pre and post
65 fatiguing exercise. To determine the contribution of central factors the twitch interpolation
66 technique is used, superimposing single or double twitches on MVC then comparing the
67 superimposed response to the potentiated response obtained from the relaxed muscle

68 Thus, the aims of the current study were to determine the effects of hyperoxia on repeated
69 cycle performance, and to assess the nature and extent of fatigue after sprinting.

70 It was hypothesised that repeated sprint cycle performance would decrease to a larger degree
71 in the normoxia condition compared with the hyperoxia condition. Second, it was
72 hypothesised that both central and peripheral components of fatigue would be reduced to a
73 greater extent in the normoxia condition.

74 **Methods**

75 Fourteen healthy males were recruited to take part in the study. Participants (1.81 ± 0.04 m,
76 77.6 ± 11.0 kg, 25.9 ± 7.3 years) were recreational cyclists who had all previously used a cycle
77 ergometer. Participants were accustomed to cycling on a weekly basis, but none had ever
78 competed at any cycling events.

79 Participants were informed of the procedure and provided informed consent. Ethical approval
80 for the study was granted by the University ethics committee.

81 This study was a within subjects design with 2 visits to the laboratory in a counter balanced
82 order, in a single blind fashion. Participants completed a series of sprints under two different
83 conditions; hyperoxia ($FiO_2 \sim 1.00$) or normoxia ($FiO_2 \sim 0.21$). Visits were separated by at
84 least 48hrs.

85 Laboratory tests were completed at the same time of the day (± 2 h). Participants were asked
86 to maintain normal activity and sleep patterns between testing sessions. Participants were
87 requested to refrain from any caffeinated products or eating three hours prior to participation.
88 Participants were asked to refrain from strenuous physical activity 24 hours prior to
89 participating.

90 Participants undertook the same procedure on both visits; 3x5s Maximal Voluntary
91 Contractions (MVC) then 15 minute relative intensity warm up at 52% of heart rate reserve
92 using the rearranged Karvonen formula^{11,12}. This was followed by 10-minute passive
93 recovery, 3x5s MVCs (pre-sprint baseline) and 10x15s cycle sprints with 45 seconds of
94 recovery. Finally, a further set of 3x5s MVCs (post-sprint). Gas administration occurred at
95 the commencement of the first sprint and continued throughout the sprints and the post
96 sprint MVC's.

97 Hyperoxic and normoxic gas mixtures were administered via a rig of 4 x 200 L Douglas bags
98 connected to a mask and head net (Hans Rudolph, Shawnee, KS, USA). The hyperoxia
99 condition used medical grade oxygen (BOC, Surrey, UK). In each condition, participants wore

100 the mask and breathed from the Douglas bag during the repeated sprints and the last set of
101 MVC's.

102 Prior to starting the protocol, a pre-exercise 20 µl capillary sample was taken from the right
103 ear lobe. Each sample was mixed with haemolysing solution within a 0.5 ml haemolysing
104 solution cup. Further samples were taken during the recovery period of each sprint repetition.
105 All samples were analysed for blood lactate within 24 hours of withdrawal using a Biosen (EKF
106 diagnostics, Cardiff, UK).

107 Muscle fatigue was assessed prior to and after the repeated sprints using electrical stimulation
108 of the right femoral nerve. **The right leg was used regardless of dominance due to**
109 **measurement restraints.** The variables obtained to assess muscle performance were;
110 maximal voluntary contraction (MVC), voluntary activation (VA) and potentiated doublet twitch
111 force (PTF). **Muscle fatigue was measured within 1 minute of exercise cessation before the**
112 **decline in force dissipates** ¹³.

113 Knee extensor force (N) during voluntary and stimulated contractions was measured using a
114 calibrated load cell dynamometer (Kin-Com, Chattanooga Group Inc., USA), attached to a
115 custom-built chair. The participant's ankle was strapped to a load cell immediately superior to
116 the right malleoli. Participants were instructed to maximally extend their leg against a static
117 load cell at 90° for 5 seconds. Femoral nerve stimulation was delivered during the middle of
118 each contraction and additionally ~5s after contraction, to determine potentiated quadriceps
119 twitch force and peripheral voluntary activation. PTF was measured as the highest force
120 produced during the three repetitions evoked by a paired pulse stimulus, administered to the
121 resting muscle via the nerve at rest, 5 seconds post the MVC¹⁴. VA was determined using the
122 interpolated doublet twitch technique and is estimated by the changes in the interpolated
123 doublet twitch relative to the PTF (equation1). The force evoked by the imposed electrical
124 stimulus on top of the MVC is the interpolated doublet twitch (IT).

125 **Eq 1. Determining voluntary activation** ¹⁵.

126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152

$$VA(\%) = \left(1 - \frac{IT}{PTF}\right) \cdot 100$$

Doublet- twitch electrical stimuli of 200µs pulse width were delivered to the right femoral nerve via surface electrodes (Axelgaard ValuTrode) and a constant current stimulator (DS7AH; Digitimer Ltd., Welwyn Garden City, UK). A signal converter was used to convert the digital signals of the computer to analogue signals of the digitimer with a sampling rate of 2000 Hz (PowerLab/4st – ML760, AD Instruments, UK). The cathode was positioned on the femoral triangle. The anode was positioned 3cm proximal to the base of the patella, whilst the knee was fully flexed¹⁶. Prior to application of the pads, the area was shaven. The electrode placement was marked with semi-permanent ink to ensure consistent placement between trials.

Prior to the MVCs, participants completed resting twitch stimuli in order to determine the maximal twitch amplitude and M-wave of the muscle at rest (the resting immediate response to an electrical stimulation). Doublet twitch stimuli were delivered starting at 100mA and increasing to 150mA then increasing in stepwise increments of 25mA, until a plateau occurred in twitch amplitude. To ensure a full and optimal stimulus the last twitch was increased by a further 30%. Offline analysis was enabled with the use of LabChart 7.0 software (AD Instruments, UK).

Following the warm up and two sets of MVCs each participant undertook 10 repetitions of 15 second cycling sprint (Watt Bike, Nottingham, UK) followed by 45 sec static recovery. Participants were instructed to stay seated to isolate leg power. The air brake was set to 10 and magnetic brake set to one to allow sufficient resistance to generate peak force, whilst not exceeding peak cadence. During each sprint and recovery period the participants breathed either normoxic or hyperoxic air via the Douglas bag system. Data used for analysis were peak sprinting power (the highest W achieved in each cycle) and mean sprint power (the average

153 W produced during each 15 sec cycle). An overall peak and an overall mean were also
154 calculated for each participant.

155

156 All statistical analysis was performed using the statistical package, SPSS statistics version 25
157 for windows (SPSS Inc, Chicago, IL, USA).

158 Paired samples t-tests (Bonferroni corrected) were conducted to examine differences
159 according to condition (hyperoxia / normoxia) for; peak power (W), mean power (W) across
160 each 15 second sprint, and blood lactate (mmol/L) for each sprint. Two-way analysis of
161 variance (ANOVA) were conducted to test the differences between MVC, VA, PT before and
162 after the repeated sprints, according to condition. Alpha was set at $p = 0.05$ for all data
163 analysis. Effect size for individual measures were calculated and reported as Cohen's d and
164 interpreted using bounds as 0.2, 0.5, > 0.8, where they are small, medium and large
165 respectively¹⁷.

166

167 **Results**

168 There was no difference in peak sprinting power (W) between the hyperoxia (753.3 ± 87.8)
169 and normoxia (761.0 ± 97.4) conditions across the 10 sprint repetitions; $t(9) = 1.09$, $p=0.304$,
170 **ES = -0.08**. However, average power was significantly higher (around 25W) in the hyperoxia
171 condition (654.6 ± 86.9) compared with the normoxia condition (629.2 ± 96.2) across the 10
172 sprint repetitions; $t(9) = -4.65$, $p= 0.001$, **ES = 0.28** (figure 1).

173 Mean blood lactate was higher in the hyperoxia condition (9.81 mmol/L), although only by a
174 small margin (0.43 mmol/L) $t(9) = 3.36$, $p=0.008$, **ES = -0.13**. When comparing sprints directly
175 between conditions, it was only after sprints 4 and 8 that this difference reached significance
176 (figure 2).

177 MVC : As expected there was a main effect of time on muscle force, ($F(1,12)=34.47$,
178 $p<0.001$, **ES = 4.14**) with a decrease in MVC post the sprints (pre 774.4 ± 46.3 vs post 587.9
179 ± 43.7) Despite a somewhat larger decline in MVC in the hyperoxia trial, there was no
180 statistical difference between conditions ($p=0.66$,) (table 1). There was no interaction effect
181 for condition x time ($p=0.08$)

182 PTF: Again a main effect was found for time ($F(1,12)=53.03$, $p<0.001$, **ES = 8.66**) with a
183 smaller potentiated doublet twitch production post sprints compared to pre-sprint (pre 459.2
184 ± 22.2 vs post 290.4 ± 16.5), but not for condition ($p=0.86$, **ES = -0.03**). There was no
185 interaction effect reported for condition x time ($p=0.31$) for PTF.

186 VA: A main effect was found for condition ($F(1,12)=8.23$, $p=0.013$, **ES = 2.23**) with a higher
187 voluntary activation in hyperoxia compared with normoxia (79.1 ± 2.2 vs 74.3 ± 2.1
188 respectively), but no effect of time ($p=0.14$). Importantly there was no interaction effect
189 reported for condition x time ($p=0.79$) for VA.

190

191

192 Discussion

193

194 The aim of this study was to identify the effects of hyperoxia on repeated sprint ability and
195 begin to examine its effects on muscle fatigue using interpolated twitch. Though peak cycling
196 power was not different between conditions, average power was higher in the hyperoxia trials,
197 by around 4%, indicating that a higher work output could be maintained in the presence of
198 extra oxygen. This higher mean power was associated with a higher blood lactate level. There
199 was no significant effect of condition on changes in muscle fatigue measures (assessed by
200 MVC and electrical stimulation).

201

202 The current study found that breathing hyperoxic air during 15 second repeated sprint efforts
203 led to a higher mean power output, (around 25 Watts), with no significant influence on peak
204 power. Hauser *et al.*,¹⁸ found that mean power was not different between the two conditions
205 in their study ($FiO_2=1.00$ and $FiO_2=0.21$). However, their methodology of 3 x 3-minute sprints
206 meant their participants were potentially predominately using a different energy system to that
207 used in a 15 second sprint. The lactic acid system and the aerobic system are the predominate
208 sources of ATP production during maximal 3-minute efforts, whereas the during 15 second
209 sprints the majority of ATP is supplied by the ATP-PC system. Second, Hauser's participants
210 experienced hyperoxia between efforts only. Timing of hyperoxia is potentially key. For
211 example, Sperlich *et al* ¹⁹ also report no difference in mean or peak power across 2 sets of 5
212 x 30 sec cycle sprints. Although nature of the exercise was more similar to the current study,
213 in contrast, their participants only had supplementary oxygen in the 6-minute recovery period
214 between sets of cycle sprints.

215

216 Hyperoxia has been shown to attenuate the onset of fatigue at a peripheral level whilst also
217 maintaining cerebral oxygenation ²⁰. In the current study, MVC, a global measure of fatigue,
218 dropped by around 20% in the normoxia condition, and by around 28% in the hyperoxia
219 condition. This shows that there was greater (albeit non-significant) muscle fatigue as a result

220 of the higher mean power output in the hyperoxia condition. Interestingly, the change in PTF
221 and %VA were broadly similar across conditions. The drop in voluntary activation (%) was
222 small and less than 1.5% different between conditions. The drop in PTF however was large,
223 although again similar between conditions (34 and 38%, Table 1). These results support the
224 findings of Thomas et al⁸, who report performance in shorter efforts is predominately curtailed
225 by peripheral measures.

226

227 The ability to maintain power throughout repeated efforts has been attributed to several factors
228 including the ability to maintain BL_a, regulate pH, to maintain neural input²¹ and importantly,
229 to replenish phosphocreatine (PC) stores. According to Linossier et al.,¹ sprint capacity is not
230 reduced to the same extent in hyperoxia due to the increased rate of cellular metabolic
231 resynthesis of PC, and adenosine triphosphate (ATP). PC resynthesis during 45 seconds of
232 recovery only replenishes ~75% of the stores²². Therefore, after sprint 5 in a series such as
233 this one would expect to see a significant performance reduction. A continued depletion of
234 ATP-PC stores and an inadequate resynthesis leads to a reduction in performance until
235 additional energy systems aid in the resynthesis process (lactic acid system). An increase in
236 peak and mean power has been attributed to an enhanced PC resynthesis during repeated
237 high intensity exercise by both Mendez- Villanueva *et al.*,²³ , and Glaister,²². Mendez-
238 Villanueva analysed PC recovery rate during 10 x 6s sprints with 30 seconds recovery and
239 found that subsequent sprinting performance (peak power) during a final single sprint was
240 increased corresponding with an 8% higher PC resynthesis.

241

242 Increasing the percentage of inspired oxygen to 100% increases the rate of PC replenishment
243 from a half-life of 25 seconds to 20 seconds^{24,25}. Hogan et al.,²⁴ used a plantar flexion exercise
244 protocol with increasing workload till exhaustion. They found that an increased rate of PC
245 resynthesis aided subsequent performance, and that hyperoxia maintained mean plantar
246 flexion power further into the ramp test protocol (1W increase every 2 minutes by pulley
247 system). This findings was replicated in the current study as mean sprinting power during

248 hyperoxia was similar to that during normoxia until **sprint 4 and** beyond where the difference
249 became statistically significant. Additionally, sprint 6 was where peak power in the normoxic
250 group appeared to decline at a greater rate than the hypoxia condition. Sprint 6 in a typical
251 series is where it has been documented the reliance on aerobic metabolism increases ²².

252

253 Interestingly, the increase in sprint performance as a result of hyperoxia was similar to that
254 seen with creatine supplementation, likely through the same mechanisms of PC resynthesis
255 ²². Additional to this enhanced rate of resynthesis, hyperoxia has been shown to attenuate the
256 build-up of metabolic by products of lactate, and inorganic phosphate (Pi)²⁶. Pi in particular is
257 detrimental to performance via inhibition of muscle afferents. Type III and IV muscle afferents
258 relay exercise induced metabolic changes in the muscles to the central nervous system. The
259 accumulation of metabolic by-products reduces the effectiveness of these afferents,
260 subsequently leading to peripheral fatigue. However, both afferents are positively influenced
261 by hyperoxia, by allowing the electrical feedback to be transmitted efficiently for longer²⁶, so
262 attenuating fatigue.

263

264 Hyperoxia elicits reductions in blood lactate at many workloads ^{1,27} and although hyperoxia
265 given during recovery periods attenuates lactate accumulation, the effects are more variable.
266 ³. Maeda et al., gave varying percentages of hyperoxia (30 to 100%) in the recovery between
267 sprints, and found that whilst overall increasing the fraction of oxygen resulted in reduced
268 blood lactate after standardised exercise, the response was dependent on the subjects'
269 fitness. In the current study, higher power outputs seen in the hyperoxia condition were
270 associated with slightly increased lactate levels. Knight *et al.*,²⁸ suggest that the increase in
271 oxygen kinetics during hyperoxia is enough to attenuate the accumulation of lactate due to the
272 increased diffusion of oxygen into the mitochondria. However, they add that that this
273 attenuation can only last so long, and after a critical point lactate levels will increase
274 exponentially. This could explain the increases in lactate that have been seen in the current
275 study.

276

277 Therefore, it is suggested that hyperoxia results in a combination of increased PC resynthesis
278 and a slightly attenuated build-up of blood lactate, leading to a 'maintained' performance
279 compared to the normoxia condition seen in the current study. Acute exposure to additional
280 oxygen appears to enhance repeated sprint performance, however, determining whether
281 chronic physiological adaptation is blunted is crucial before its widespread use as a training
282 tool can be advised.

283

284 **Limitations**

285 We acknowledge several limitations of this study. Participants were required to avoid
286 strenuous exercise 24hrs prior to testing but it is noted that the effects of training may be
287 evident for 48/72 hrs. To minimise the effects of this, participants were requested to mimic the
288 training three days prior to testing before both visits. Further, no direct measure of fitness ($\dot{V}O_2$
289 max) was conducted to characterise the study population. Level of fitness is a potential
290 mediator of response to hyperoxia. Additionally, hydration status was not measured prior to
291 testing, but participants were instructed to attend testing in a hydrated state.

292

293 **Conclusion**

294 Whilst supplementary oxygen does not increase peak power during repeated sprints,
295 participants were able to maintain a higher mean power output (across the 10 sprints). Indices
296 of fatigue (MVC, PFT and VA) changed to a similar extent across conditions in response to
297 the cycling, but the largest drop was in PFT, suggesting fatigue to be predominately peripheral
298 in nature.

299

300 **Practical implications**

- 301 - Supplementary oxygen given during a single **sprint**-based cycling session can assist
302 in reducing the extent that performance **decreases**.
- 303 - Peak power output cannot be increased with supplementary oxygen

304 - Long term effects of the use of oxygen during training are not known and therefore its
305 use as a chronic training tool is not yet advised

306

307 **Acknowledgements**

308 The authors have no conflicts of interest relevant to the content of this manuscript. No external
309 funding was provided for this project.

310 **References**

- 311 1. Linossier, Dormois D, Arsac, et al. Effect of hyperoxia on aerobic and anaerobic
312 performances and muscle metabolism during maximal cycling exercise. *Acta Physiol*
313 *Scand.* 2000;168(3):403–11.
- 314 2. Kay B, Stannard SR, Morton RH. Hyperoxia during recovery improves peak power
315 during repeated wingate cycle performance. *Brazilian J Biomotricity.* 2008;2(2):92–
316 100.
- 317 3. Maeda T, Yasukouchi A. Blood lactate disappearance during breathing hyperoxic gas
318 after exercise in two different physical fitness groups--on the workload fixed at 130%
319 AT. Vol. 17, *Journal of Physiological Anthropology.* 1998. p. 33–40.
- 320 4. Welch HG. Hyperoxia and human performance: A brief review. *Med Sci Sport Exerc.*
321 1982;14(4):253–62.
- 322 5. Nummela A, Hämäläinen I, Rusko H. Effect of hyperoxia on metabolic responses and
323 recovery in intermittent exercise. *Scand J Med Sci Sport.* 2002;12(5):309–15.
- 324 6. Gandevia SC. Spinal and Supraspinal Factors in Human Muscle Fatigue. *Physiol*
325 *Rev.* 2001;81(4):1725–89.
- 326 7. Noakes TD, Peltonen JE, Rusko HK. Evidence that central governor regulates
327 exercise performance during acute hypoxia and hyperoxia. *J Exp Biol.*
328 2001;204(1):3225–34.
- 329 8. Thomas K, Goodall S, Stone M, et al. Central and peripheral fatigue in male cyclists
330 after 4-, 20-, and 40-km time trials. *Med Sci Sports Exerc.* 2014;47(3):537–46.
- 331 9. Girard O, Bishop DJ, Racinais S. Neuromuscular Adjustments of the Quadriceps
332 Muscle after Repeated Cycling Sprints. *PLoS One.* 2013;8(5).
- 333 10. Racinais S, Bishop D, Denis R, et al. Muscle deoxygenation and neural drive to the

- 334 muscle during repeated sprint cycling. *Med Sci Sports Exerc.* 2007;39(2):268–74.
- 335 11. Karvonen MJ, Kentala E, Mustala O. The effects of training on heart rate; a
336 longitudinal study. Vol. 35, *Annales Medicinæ Experimentalis et Biologiae Fenniae.*
337 1957. p. 307–15.
- 338 12. Lounana J, Campion F, Noakes TD, et al. Relationship between %HRmax, %HR
339 reserve, % $\dot{V}O_2$ max, and % $\dot{V}O_2$ reserve in elite cyclists. *Med Sci Sports Exerc.*
340 2007;39(2):350–7.
- 341 13. Froyd C, Millet GY, Noakes TD. The development of peripheral fatigue and short-term
342 recovery during self-paced high-intensity exercise. *J Physiol.* 2013;591(5):1339–46.
- 343 14. Merton PA. Voluntary strength and fatigue. *J Physiol.* 1954;123(3):553–64.
- 344 15. Konings MJ, Parkinson J, Zijdwind I, et al. Racing an Opponent Alters Pacing,
345 Performance and Muscle Force Decline, But Not RPE. *Int J Sports Physiol Perform.*
346 2017;1–24.
- 347 16. Goodall S, González-Alonso J, Ali L, et al. Supraspinal fatigue after normoxic and
348 hypoxic exercise in humans. *J Physiol.* 2012;590(Pt 11):2767–82.
- 349 17. Cohen J. *Statistical Power Analysis for the Behavioural Sciences.* 2nd ed. New York:
350 Lawrence Erlbaum Associates; 1988. 0–559 p.
- 351 18. Hauser A, Zinner C, Born DP, et al. Does hyperoxic recovery during cross-country
352 skiing team sprints enhance performance? *Med Sci Sports Exerc.* 2014;46(4):787–94.
- 353 19. Billy S, Zinner C, Krueger M, et al. Effects of hyperoxia during recovery from 5×30-s
354 bouts of maximal-intensity exercise. *J Sports Sci.* 2012;30(9):851–8.
- 355 20. Nielsen HB, Boushel R, Madsen P, et al. Cerebral desaturation during exercise
356 reversed by O₂ supplementation. *Am J Physiol.* 1999;277(3 Pt 2):H1045-52.
- 357 21. Juel C. Regulation of pH in human skeletal muscle: Adaptations to physical activity.

- 358 *Acta Physiol.* 2008;193(1):17–24.
- 359 22. Glaister M. Multiple sprint work: Physiological responses, mechanisms of fatigue and
360 the influence of aerobic fitness. *Sport Med.* 2005;35(9):757–77.
- 361 23. Mendez-Villanueva A, Edge J, Suriano R, et al. The Recovery of Repeated-Sprint
362 Exercise Is Associated with PCr Resynthesis, while Muscle pH and EMG Amplitude
363 Remain Depressed. *PLoS One.* 2012;7(12):4–13.
- 364 24. Hogan MC, Haseler LJ, Richardson RS. Human Muscle Performance and PCr
365 hydrolysis with varied Inspired Oxygen Fractions: A 31P-MRS Study. *J Appl Physiol.*
366 1999;86(4):1367–73.
- 367 25. Wallimann T, Dolder M, Schlattner U, et al. Some new aspects of creatine kinase
368 (CK): compartmentation, structure, function and regulation for cellular and
369 mitochondrial bioenergetics and physiology. *BioFactors.* 1998;8(3–4):229–34.
- 370 26. Amann M. Central and peripheral fatigue: Interaction during cycling exercise in
371 humans. *Med Sci Sports Exerc.* 2011;43(11):2039–45.
- 372 27. Sperlich B, Calbet JALL, Boushel R, et al. Is the use of hyperoxia in sports effective,
373 safe and ethical? *Scandinavian Journal of Medicine and Science in Sports.*
374 2016;26(11):1–5.
- 375 28. Knight DR, Schaffartzik W, Poole DC, et al. Effects of hyperoxia on maximal leg O₂
376 supply and utilization in men. *J Appl Physiol.* 1993;75(6):2586–94.

377

378

379

380

381

382 **Table 1:** Neuromuscular function of the knee extensors; Maximal Voluntary contraction
 383 (MVC), potentiated doublet twitch (PTF) and voluntary activation (VA) (n = 14).

	Normoxia			Hyperoxia		
	Pre-Sprint	Post Sprints	% Difference	Pre-Sprint	Post Sprints	% Difference
MVC (N)	762.6 ± 169.1	611.3 ± 150.6	19.8	786.1 ± 187.0	564.4 ± 204.6	28.2
PTF (N)	452.1 ± 86.0	295.4 ± 64.0	34.6	466.2 ± 95.5	285.4 ± 67.4	38.8
VA (%)	75.8 ± 10.0	72.8 ± 9.7	3.9	81.2 ± 10.3	77.1 ± 9.6	5.0

384

385

386

387

388

389 **Figure 1.** Mean sprinting power across 10 sprints (n = 14). * significant difference
 390 between conditions (Hyperoxia and Normoxia) (p< 0.05).

391

392

393

394

395 **Figure 2.** Mean blood lactate concentration (mmol/L) over 10 sprints (n = 14). *
 396 significant difference between condition (Hyperoxia and normoxia) (p< 0.05).

397 Supplementary Table

398 Table 1. Mean ± SD and Cohens D effect Sizes for three variables in each condition for each of the 10 repeat cycling sprints (n =14).

<i>Sprint No.</i>	<i>One</i>	<i>Two</i>	<i>Three</i>	<i>Four</i>	<i>Five</i>	<i>Six</i>	<i>Seven</i>	<i>Eight</i>	<i>Nine</i>	<i>Ten</i>
Mean Power										
<i>Normoxia</i>	842.46 ± 105.17	724.96 ± 92.88	685.49 ± 98.34	634.51 ± 103.25	606.80 ± 110.01	564.59 ± 111.96	558.25 ± 103.31	541.18 ± 104.65	557.90 ± 99.21	575.75 ± 115.21
<i>Hyperoxia</i>	828.89 ± 139.45	770.36 ± 129.76	696.71 ± 110.11	671.37 ± 125.76	632.03 ± 120.82	592.14 ± 120.60	579.30 ± 115.21	585.90 ± 104.63	588.79 ± 107.63	600.38 ± 119.93
<i>ES</i>	-0.11	0.40	0.11	0.32	0.22	0.24	0.19	0.43	0.30	0.21
Peak Power										
<i>Normoxia</i>	958.29 ± 120.03	862.57 ± 109.61	835.79 ± 99.77	776.29 ± 111.79	732.36 ± 113.37	699.14 ± 128.97	680.79 ± 106.48	655.62 ± 115.01	674.42 ± 114.36	734.83 ± 148.52
<i>Hyperoxia</i>	921.27 ± 115.22	870.99 ± 88.89	798.44 ± 96.66	786.48 ± 142.55	730.92 ± 124.85	684.57 ± 150.55	673.17 ± 137.09	678.97 ± 132.18	687.38 ± 124.47	921.27 ± 133.62
<i>ES</i>	-0.31	0.08	-0.38	0.08	-0.01	-0.10	-0.06	0.19	0.11	1.32
Blood lactate										
<i>Normoxia</i>	3.05 ± 1.64	5.02 ± 1.57	7.08 ± 2.86	8.44 ± 2.68	10.14 ± 3.18	10.74 ± 3.28	11.98 ± 3.79	12.47 ± 3.80	12.00 ± 3.50	12.85 ± 3.30
<i>Hyperoxia</i>	2.87 ± 0.59	5.36 ± 1.74	7.48 ± 2.01	9.50 ± 2.33	10.57 ± 3.31	11.34 ± 3.09	12.28 ± 2.75	12.79 ± 2.55	13.10 ± 2.68	12.81 ± 2.93
<i>ES</i>	-0.15	0.21	0.16	0.42	0.14	0.19	0.09	0.10	0.35	-0.01

399